Europe-based Aptar Pharma, the world’s leading supplier of innovative non-invasive drug delivery devices, organized the fourth symposium on Advances in Respiratory Innovation and Technology. The company collaborated with the SFDA (Chinese State Food and Drug Administration) training centre, to organize the event which was held at Shanghai, from September 21 to September 23, 2011.

The three day event was viewed as a key biennial meeting in China to share the advances in inhalation science and technology innovation.

The scientific symposium hosted more than 150 participants from China, Europe and the USA. A panel of 23 highly renowned speakers debated current domestic Chinese and foreign HFA aerosol regulations. Other topics addressed were the market outlook, and future development trends of aerosols including Dry Powder Inhalers and nasal sprays.

Dr Ping Wang, SFDA National Pharmacopeia committee provided an overview of SFDA quality requirements for inhaled drugs. Dr Qiming Zhang, National Institute for Food and Drug Control spoke on the ‘Control of related substance profiles in inhaled drugs.’ Dr Huimin Sun, National Institutes for Food and Drug Control address the quality requirements of HFA from SFDA.

Other speakers included Dr Guiliang Chen, Shanghai Institute for Food and Drug Control, Dr Dave Parkins, GSK: Dr Tushar Shah, Teva, Dr Xian-Ming Zeng, Teva, Dr Gerallt Williams, Aptar Pharma, Dr Hak-Kim Chan, University of Sydney, Dr Guillaume Brouet, Aptar Pharma.

In China, Aptar Pharma set-up operations at Suzhou, near Shanghai and has over 265 employees working out it advanced production centre. The facility provides innovative and proven aerosol, spray and dispensing systems, to biotechnology, healthcare and pharmaceutical companies in China.

According to Marc Prieur, president Aptar Pharma Asia, being a leader in China, we were able to contribute to the event with SFDA training centre. Considerable interest was evinced both from China and other global participants.

The Prescription Division has been able to provide the advances in respiratory innovation and technology. Which included a Metered Dose Inhaler, he added.